- Trials with a EudraCT protocol (421)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
421 result(s) found for: Ventilation rate.
Displaying page 3 of 22.
EudraCT Number: 2020-001953-36 | Sponsor Protocol Number: GC2005 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects w... | ||||||||||||||||||
Medical condition: Patients with Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000417-16 | Sponsor Protocol Number: Uni-Köln-4480 | Start Date*: 2021-10-20 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 | |||||||||||||
Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004599-20 | Sponsor Protocol Number: PHRCN_2018_BACHOUMAS | Start Date*: 2021-07-27 |
Sponsor Name:CHU DE CLERMONT-FERRAND | ||
Full Title: Effects of early testosterone gel administration on physical performance in the critically ill: a randomised double blind clinical trial | ||
Medical condition: Patients receiving invasive mechanical ventilation and treatment with a vasoactive drug within 96 hours of ICU admission will be screened. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001052-18 | Sponsor Protocol Number: 010 | Start Date*: 2020-03-25 | |||||||||||
Sponsor Name:Regents of the University of Minnesota | |||||||||||||
Full Title: A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European U... | |||||||||||||
Medical condition: Influenza COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) DE (Completed) GR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001909-22 | Sponsor Protocol Number: APHP200461 | Start Date*: 2020-04-29 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA: A RANDOMIZED CONTROLLED DO... | ||
Medical condition: Patients with hypoxemic acute respiratory failure due to COVID-19-related pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003403-33 | Sponsor Protocol Number: MIT-Co001-C101 | Start Date*: 2021-01-20 | |||||||||||
Sponsor Name:NEURALIS s.a. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of patients with Confirmed SARS-CoV-2 Infection | |||||||||||||
Medical condition: Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with moderate COVID-19. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001860-27 | Sponsor Protocol Number: UoL001542 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment | |||||||||||||
Medical condition: Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001290-74 | Sponsor Protocol Number: SARICOVID | Start Date*: 2020-04-11 | |||||||||||
Sponsor Name:Consorci Parc de Salut Mar (PSMAR) | |||||||||||||
Full Title: Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care | |||||||||||||
Medical condition: Patients with confirmed COVID-19 infection and criteria for mild-moderate pneumonia (CURB-65 ≤1 i SatO2 ≥90%, MEWS score less than 3) and IL6 values of 20 pg / ml, will be randomly assigned to a sa... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003274-32 | Sponsor Protocol Number: 2015/233 | Start Date*: 2016-07-13 |
Sponsor Name:Dra Maria Luz Couce
[...]
1. Dra Maria Luz Couce
2. Dr. José Luis Fernández Trisac |
||
Full Title: Effect of caffeine citrate in acute bronchiolitis symptoms of apnea in neonates and infants during the first three months of life | ||
Medical condition: Children under 3 years with acute RSV bronchiolitis which present breaks apnea | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001381-11 | Sponsor Protocol Number: APHP200409 | Start Date*: 2020-04-08 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: ... | ||
Medical condition: Adult patients with a diagnosis of COVID-19 requiring hospitalization in a non-ICU and on prior therapy with RAS blockers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001475-33 | Sponsor Protocol Number: COLVID-19 | Start Date*: 2020-04-10 | |||||||||||||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA | |||||||||||||||||||||||
Full Title: Treatment with COLchicine of patients affected by COVID-19: a Pilot Study | |||||||||||||||||||||||
Medical condition: Study population: patients with COVID-19 pneumonia with oxygen saturation deficiency and requiring hospitalization assistance. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002230-32 | Sponsor Protocol Number: | Start Date*: 2020-06-23 |
Sponsor Name:University of Edinburgh
[...]
1. University of Edinburgh
2. NHS Lothian |
||
Full Title: Rapid Experimental Medicine for COVID-19 | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001662-11 | Sponsor Protocol Number: CINC424J12301 | Start Date*: 2020-05-05 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) | ||
Medical condition: COVID-19 associated cytokine storm | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002184-22 | Sponsor Protocol Number: NS3 | Start Date*: 2021-05-14 | |||||||||||
Sponsor Name:Athens Medical Society | |||||||||||||
Full Title: A phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 in 10^9 dose versus 10^10 dose, for the prevention of clinical deterioration in pa... | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001794-77 | Sponsor Protocol Number: SilCOVID19 | Start Date*: 2020-06-10 |
Sponsor Name:INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA | ||
Full Title: Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infect... | ||
Medical condition: COVID19 respiratory failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004571-41 | Sponsor Protocol Number: RBMinCovid19 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Cyxone AB | |||||||||||||
Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19) | |||||||||||||
Medical condition: Coronavirus Disease (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005931-58 | Sponsor Protocol Number: APHP200043 | Start Date*: 2021-04-02 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: ACTIVE : ACid tranexamic or Terlipressin for Initial emergency treatment of mild to seVere hEmoptysis | ||
Medical condition: Hemoptysis, whatever the cause, with the exception of cystic fibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001825-29 | Sponsor Protocol Number: ANA-COVID-GEAS | Start Date*: 2020-04-28 |
Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
Full Title: CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 | ||
Medical condition: Hyperinflammation and respiratory distress in patients with SARS- CoV-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-008439-28 | Sponsor Protocol Number: 1682/08 | Start Date*: 2009-03-22 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Effects of the addition of haloperidol on propofol requirements during sedation with propofol and remifentanil | |||||||||||||
Medical condition: analgo-sedation in mechanically ventilated patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001481-11 | Sponsor Protocol Number: RuxCoFlam | Start Date*: 2020-04-22 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation | |||||||||||||
Medical condition: Covid-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
